What is ViOptix?
ViOptix operates at the intersection of advanced medical engineering and clinical surgery, specializing in the development of real-time tissue oximetry solutions. The company's flagship product portfolio, which includes the T.Ox, T.Ox Remote, and Intra.Ox systems, is engineered to provide healthcare professionals with precise data regarding tissue oxygen saturation. These diagnostic tools are particularly vital in high-stakes clinical environments such as breast reconstruction, where monitoring tissue viability is essential for improving patient outcomes. By providing actionable insights, ViOptix empowers surgeons to make informed, real-time decisions, thereby reducing complications and enhancing the overall standard of care in surgical settings.
How much funding has ViOptix raised?
ViOptix has raised a total of $24.4M across 3 funding rounds:
Series C
$9.2M
Series D
$12.2M
Series E
$3M
Series C (2004): $9.2M with participation from IN-vivo Ventures, Morningside Group, MDS Capital, and Trident Investments
Series D (2008): $12.2M led by Morningside Venture Investments
Series E (2010): $3M, investors not publicly disclosed
Key Investors in ViOptix
Morningside Venture Investments
Founded in 1986 by the Chan family, this firm focuses on private equity and venture capital investments, leveraging deep industry knowledge and a commitment to social responsibility.
MDS Capital
A Vancouver-based venture capital and private equity firm that provides strategic financial support to companies within the healthcare and life sciences sectors.
IN-vivo Ventures
A specialized investment firm focused on supporting early-to-growth stage life science companies through strategic capital and industry expertise.
What's next for ViOptix?
With the successful completion of this major enterprise-level funding round, ViOptix is well-positioned to scale its operational footprint and accelerate the adoption of its oximetry technology across global healthcare institutions. The strategic allocation of this capital will likely focus on expanding clinical evidence programs and refining the next generation of diagnostic hardware. As the company transitions from its established growth phase into a broader market penetration strategy, the focus remains on maintaining its leadership in surgical monitoring. Future initiatives will likely prioritize the integration of its remote monitoring capabilities into standard hospital workflows, ensuring that the firm remains at the forefront of medical innovation and patient safety.
See full ViOptix company page
